Recent press releases

01. February 2016

Formycon appoints biotech expert Professor Johannes Buchner to the Advisory Board

Munich – The biosimilars company Formycon is underpinning its claim to scientific excellence by appointing Johannes Buchner, professor in Biotechnology at the Technische Universität München (Technical University of Munich) and President of the German Society for Biochemistry and Molecular Biology (GBM), to its Advisory Board. Professor Buchner is a globally recognized expert in biotechnological research and development.

After studying Biology and receiving his PhD from the University of Regensburg in 1991, Buchner investigated new concepts in cancer treatment during his postdoctoral stay at the National Institutes of Health in Bethesda, USA. He returned to the University of Regensburg as a group leader, and since 1998 he is a Professor for Biotechnology at the Technische Universität München, Germany. His research focuses on chaperone proteins and antibodies. Buchner is a member of the German Academy of Sciences (Leopoldina) as well as the Bavarian Academy of Sciences and Humanities. He has received numerous awards for his research, including the Hans Neurath Award from the Protein Society and the Schleiden Medal awarded by Leopoldina.

“I am delighted that we have been able to welcome Professor Johannes Buchner, a highly renowned professional in the field of molecular biology and antibody research. His expertise will play a significant role in our Advisory Board and will support our development work”, comments Dr. Carsten Brockmeyer, CEO of Formycon AG.

In addition to Professor Buchner, the board consists of Dr. Gerhard Schaefer und Dr. Bernhard Hampl, who are both highly experienced managers and proven industry experts from the pharmaceutical sector.

 

About Formycon:
Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s specialist expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has three biosimilars under development, with further product candidates already identified. Two biosimilar candidates have been licensed out to Santo Holding GmbH.

 

Disclaimer:
This press release may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here.
Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety and patent litigation. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful.

Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated.

This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended.

This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.